Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics.

[1]  H. Ohishi,et al.  Transcatheter hepatic segmental arterial embolization using lipiodol mixed with an anticancer drug and gelfoam particles for hepatocellular carcinoma , 1990, CardioVascular and Interventional Radiology.

[2]  Donald L. Miller,et al.  Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy. , 2006, Journal of vascular and interventional radiology : JVIR.

[3]  A. Lloyd,et al.  DC bead: in vitro characterization of a drug-delivery device for transarterial chemoembolization. , 2006, Journal of vascular and interventional radiology : JVIR.

[4]  C. Georgiades,et al.  Effects of the type of embolization particles on carboplatin concentration in liver tumors after transcatheter arterial chemoembolization in a rabbit model of liver cancer. , 2005, Journal of vascular and interventional radiology : JVIR.

[5]  J. Bruix,et al.  Management of hepatocellular carcinoma , 2005, Hepatology.

[6]  Josepa Ribes,et al.  Primary liver cancer: worldwide incidence and trends. , 2004, Gastroenterology.

[7]  J. Bruix,et al.  Chemoembolization for hepatocellular carcinoma. , 2004, Gastroenterology.

[8]  R. Guillevin,et al.  In vitro study of the compatibility of tris-acryl gelatin microspheres with various chemotherapeutic agents. , 2003, Journal of vascular and interventional radiology : JVIR.

[9]  J. Bruix,et al.  Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival , 2003, Hepatology.

[10]  D. Ball,et al.  In vitro stability of tris-acryl gelatin microspheres in a multipharmaceutical chemoembolization solution. , 2003, Journal of vascular and interventional radiology : JVIR.

[11]  M. Choti,et al.  Influence of a new prophylactic antibiotic therapy on the incidence of liver abscesses after chemoembolization treatment of liver tumors. , 2002, Journal of vascular and interventional radiology : JVIR.

[12]  Ramon Planas,et al.  Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial , 2002, The Lancet.

[13]  John Wong,et al.  Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma , 2002, Hepatology.

[14]  O. Matsui,et al.  Accumulation of Iodized Oil Within the Non-Neoplastic Liver Adjacent to Hepatocellular Carcinoma via the Drainage Routes of the Tumor After Transcatheter Arterial Embolization , 2001, CardioVascular and Interventional Radiology.

[15]  Jacques Ferlay,et al.  Estimating the world cancer burden: Globocan 2000 , 2001, International journal of cancer.

[16]  L Pagliaro,et al.  Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. , 2001, Journal of hepatology.

[17]  M. Soulen,et al.  Risk factors for liver abscess formation after hepatic chemoembolization. , 2001, Journal of vascular and interventional radiology : JVIR.

[18]  W. M. Lam,et al.  A randomized clinical trial comparing autologous blood clot and gelfoam in transarterial chemoembolization for inoperable hepatocellular carcinoma. , 2000, Journal of hepatology.

[19]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[20]  J. Verweij,et al.  Determination of doxorubicin and doxorubicinol in plasma of cancer patients by high-performance liquid chromatography. , 1999, Analytical Biochemistry.

[21]  O. Ernst,et al.  Treatment of hepatocellular carcinoma by transcatheter arterial chemoembolization: comparison of planned periodic chemoembolization and chemoembolization based on tumor response. , 1999, AJR. American journal of roentgenology.

[22]  J. Bruix,et al.  Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification , 1999, Seminars in liver disease.

[23]  M. Kusano,et al.  Prospective and randomized trial of lipiodol-transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma: a comparison of epirubicin and doxorubicin (second cooperative study). The Cooperative Study Group for Liver Cancer Treatment of Japan. , 1997, Seminars in oncology.

[24]  T. de Baère,et al.  Liver abscess formation after local treatment of liver tumors , 1996, Hepatology.

[25]  R. Yamada,et al.  [Alginate gel beads for chemoembolization: initial report]. , 1995, Nihon Igaku Hoshasen Gakkai zasshi. Nippon acta radiologica.

[26]  J. Bruix,et al.  Transarterial embolization for hepatocellular carcinoma. Antibiotic prophylaxis and clinical meaning of postembolization fever. , 1995, Journal of hepatology.

[27]  N. Dobbs,et al.  Pharmacokinetics and toxicity of intraarterial adriamycin for hepatocellular carcinoma: effect of coadministration of lipiodol. , 1991, Journal of hepatology.

[28]  P. Johnson,et al.  Intraarterial adriamycin and lipiodol for inoperable hepatocellular carcinoma: a comparison with intravenous adriamycin. , 1990, Journal of hepatology.

[29]  J. Barbare,et al.  Hepatic extraction of adriamycin in patients with hepatocellular carcinoma. , 1984, European journal of cancer & clinical oncology.